Navigation Links
Genomic Health Announces Study Confirming Prognostic Value of Oncotype DX(R) Recurrence Score(R) Result in Japanese Breast Cancer Patients

- Results of International Multi-Center Study Consistent with Suite of U.S. and European Clinical Studies Evaluating Oncotype DX -

REDWOOD CITY, Calif. and KYOTO, Japan, April 20 /PRNewswire-FirstCall/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced results of a multi-center Japanese study demonstrating that the Oncotype DX breast cancer assay had significant prognostic value in Japanese women with estrogen receptor-positive early-stage breast cancer. Oncotype DX identified a large portion of patients in Japan who had estrogen receptor-positive early-stage breast cancer as having a low likelihood of distant recurrence. Researchers from the Japan Breast Cancer Research Group presented results in an oral presentation at the 2009 Kyoto Breast Cancer Consensus Conference International Convention in Kyoto, Japan on April 17.

Oncotype DX has been available in Japan since 2007 via SRL, Inc., the exclusive distributor of Oncotype DX in Japan.

"These results highlight the clinical utility of this assay for treatment planning for early-stage breast cancer across populations, including patients in Japan with breast cancer," said Masakazu Toi, M.D., Ph.D., Professor of the Department of Surgery at Kyoto University School of Medicine and a director of the Japan Breast Cancer Research Group. "Based on these results, we believe that Oncotype DX should be integrated into standard breast cancer treatment planning for patients in Japan."

Researchers evaluated tumor samples from 200 patients with early-stage, estrogen receptor-positive, lymph node negative breast cancer, who were treated with tamoxifen, and who had surgery between 1992 and 1998. The Oncotype DX breast cancer assay was performed on all individual tumor specimens and the continuous Recurrence Score(R) was strongly associated with the risk of distant recurrence (p<0.001). In addition, these patients were categorized into Recurrence Score groups based on the standard cutoff points of 18 and 31; 48 percent had a Recurrence Score less than 18, 20 percent had a Recurrence Score between 18 and 30, and 33 percent had a Recurrence Score greater than or equal to 31. The distribution of Recurrence Scores in the Japanese population was similar to that found in previous multicenter studies performed in the United States. Finally, as shown consistently across multiple Oncotype DX studies, the risk of distant recurrence in the group with a Recurrence Score less than 18 (3% at 10 years) was shown to be significantly lower than the group with a Recurrence Score greater than or equal to 31 (25% at 10 years) (p<0.001). A large proportion of breast cancer patients in Japan were identified by the Recurrence Score to have a low likelihood of distant recurrence when treated with tamoxifen alone without chemotherapy.

About Oncotype DX(R)

The Oncotype DX breast cancer assay is the first and only multi-gene expression test commercially available that has clinical evidence validating its ability to predict the likelihood of chemotherapy benefit as well as recurrence in early-stage breast cancer. Additionally, the test report provides quantitative scores for certain individual genes. The Oncotype DX breast cancer assay has been extensively evaluated in eleven clinical studies involving more than 4,000 breast cancer patients, including a large validation study published in The New England Journal of Medicine and a chemotherapy benefit study published in the Journal of Clinical Oncology. As of December 31, 2008, 7,500 physicians have ordered more than 85,000 tests, and both Medicare and private health plans covering approximately 90 percent of U.S. insured lives provided reimbursement for Oncotype DX through contracts, agreements or policy decisions. Both the American Society of Clinical Oncology (ASCO) and the National Comprehensive Cancer Network recommend the use of Oncotype DX for patients with node-negative breast cancer that is estrogen-receptor positive and/or progesterone-receptor positive. For more information about Oncotype DX, please visit

About Genomic Health

Genomic Health, Inc. (Nasdaq: GHDX) is a life science company focused on the development and commercialization of genomic-based clinical laboratory services for cancer that allow physicians and patients to make individualized treatment decisions. In 2004, Genomic Health launched its first test, Oncotype DX(R), which has been shown to predict the likelihood of breast cancer recurrence and the likelihood of chemotherapy benefit in a large portion of early-stage breast cancer patients. The company was founded in 2000 and is located in Redwood City, California. For more information, please visit

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the applicability of clinical study results to actual outcomes and the belief that Oncotype DX should be integrated into standard breast cancer treatment planning for patients in Japan. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially, and reported results should not be considered as an indication of future performance. These risks and uncertainties include, but are not limited to: the risk that we may not obtain or maintain sufficient levels of reimbursement for our tests; the risks and uncertainties associated with the regulation of our tests; the applicability of clinical study results to actual outcomes; and the other risks set forth in the company's filings with the Securities and Exchange Commission, including the risks set forth in the company's Annual Report on Form 10-K for the year ended December 31, 2008. These forward-looking statements speak only as of the date hereof. Genomic Health disclaims any obligation to update these forward-looking statements.

NOTE: The Genomic Health logo, Oncotype, Oncotype DX and Recurrence Score are trademarks or registered trademarks of Genomic Health, Inc. All other trademarks and service marks are the property of their respective owners.

SOURCE Genomic Health
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Anemia and tropical diseases; Is pharmacogenomics ready for the clinic?
2. Microarray provides 3 genomic guides to breast cancer treatment decisions
3. Genomic Health Announces Multiple Studies on Oncotype DX(TM) Presented at 2007 American Society of Clinical Oncology (ASCO) Breast Cancer Symposium
4. Genomic Health to Present at ThinkEquity Partners Fifth Annual Growth Conference
5. Genomic profiling of lung tumors helps doctors choose most effective treatment
6. Genomic technologies to identify toxic chemicals should be developed
7. Medco, LabCorp Strike Strategic Agreement for Research on Personalized Medicine and Pharmacogenomics
8. Genomic Health Reports Inclusion of Oncotype DX(TM) in American Society of Clinical Oncology Guidelines
9. Virginia Commonwealth University to Study Genomics-Based Diagnostic Test:
10. Millennium Announces MLN1202 Significantly Reduced Marker of Systemic Inflammation and Identifies Genomic Biomarker For Responders
11. Genomic Health to Present at JMP Securities Healthcare Focus Conference
Post Your Comments:
(Date:11/24/2015)... City, UT (PRWEB) , ... November 24, 2015 , ... ... Forbes Magazine. For a business, it is critical that the first impression be positive ... business, they are not likely to buy anything or want to return. They will ...
(Date:11/24/2015)... ... 2015 , ... In response to recent news highlighting Oxycodone fraud, Novus Medical ... the United States grew 400 percent between 1999 and 2010, far more than the ... percent of all fatal drug overdoses. (1) , While oxycodone and the extended release ...
(Date:11/24/2015)... ... November 24, 2015 , ... The American Association ... their local poison centers through donations on Tuesday, Dec. 1, 2015. Since 2012, ... day that inspires people to collaborate in improving their local communities and help ...
(Date:11/24/2015)... ... 24, 2015 , ... With Thanksgiving right around the corner, holiday travel season ... protect your family and vehicle. , According to the National Highway Traffic Safety Administration, ... is sharing the following safety tips from the NHTSA: , ...
(Date:11/24/2015)... ... November 24, 2015 , ... Abington Hospital ... Aetna Institute of Quality® Bariatric Surgery Facility for treating individuals living with morbid ... health care services available to its members to help them make informed decisions ...
Breaking Medicine News(10 mins):
(Date:11/24/2015)... , Nov. 24, 2015   HeartWare International, Inc ... less-invasive, miniaturized circulatory support technologies that are revolutionizing the ... and Chief Executive Officer Doug Godshall is ... Annual Healthcare Conference on December 1, 2015 at ... 1-2 in New York . ...
(Date:11/24/2015)... 24, 2015  Ascendant Solutions, Inc. (Pink Sheets: ASDS ... of Directors has declared a special 1 percent stock dividend ... payable December 14, 2015, to shareholders of record December 7, ... additional shares of common stock. --> ... a strong endorsement of our confidence in Ascendant,s growth strategy ...
(Date:11/24/2015)... Nov. 24, 2015  Figure 1, a free mobile-first ... medical cases, has launched a new completely redesigned web ... version allows radiologists, who work primarily on a desktop, ... engage with its radiologist user base, Figure 1 is ... North America (RSNA) Annual Meeting. ...
Breaking Medicine Technology: